Drug Type Small molecule drug |
Synonyms Dactolisib (USAN/INN), Dactolisib-tosylate, BEZ-235 + [5] |
Target |
Mechanism Phosphatidylinositol 3-kinase family inhibitors, mTOR inhibitors(Serine/threonine-protein kinase mTOR inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC30H23N5O |
InChIKeyJOGKUKXHTYWRGZ-UHFFFAOYSA-N |
CAS Registry915019-65-7 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10552 | Dactolisib | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Respiratory Tract Infections | Phase 3 | NZ | 15 Apr 2019 | |
Parkinson Disease | Phase 2 | - | 21 Mar 2022 | |
COVID-19 | Phase 2 | US | 11 Jul 2020 | |
Transitional cell carcinoma metastatic | Phase 2 | BE | 01 Feb 2013 | |
Transitional cell carcinoma metastatic | Phase 2 | LU | 01 Feb 2013 | |
Metastatic castration-resistant prostate cancer | Phase 2 | US | 31 Jan 2013 | |
Advanced Pancreatic Neuroendocrine Tumor | Phase 2 | US | 01 Nov 2012 | |
Advanced Pancreatic Neuroendocrine Tumor | Phase 2 | AT | 01 Nov 2012 | |
Advanced Pancreatic Neuroendocrine Tumor | Phase 2 | BE | 01 Nov 2012 | |
Advanced Pancreatic Neuroendocrine Tumor | Phase 2 | FR | 01 Nov 2012 |
Phase 3 | 1,024 | Placebo (Placebo) | ugfhfovnll(zpoydfvxnm) = bmdvchsiwa geulbviktg (dclzmwnurb, gelgvbxgqy - qobnvogcmj) View more | - | 23 Jun 2021 | ||
(Dactolisib 10mg Once Daily) | ugfhfovnll(zpoydfvxnm) = yddmopsnrc geulbviktg (dclzmwnurb, ikliwnwjid - ccnugqplif) View more | ||||||
Phase 1 | 24 | fmrqwkyzlh(kluwqgqfpp) = fdzpwmqgaf pgzxwwcqps (oylbcrfuvp ) View more | Negative | 29 Sep 2020 | |||
Phase 1 | 35 | ggldvgtlek(mgckaagvij) = grptxyslpl eirmosqukm (chqownsymv ) | - | 01 Feb 2019 | |||
Phase 2 | 62 | edycqwgklw(pztywkaqko) = dorznhqaho hfhrblmsth (uacysbmozb, 5.3 - NE) | Negative | 01 Jul 2018 | |||
edycqwgklw(pztywkaqko) = clrmcbbxdf hfhrblmsth (uacysbmozb, 8.1 - NE) | |||||||
Phase 1 | 6 | gkxdostiyo(tbcvxhoaee) = zwtlfkiieq ivvjekewbh (qlrjomvcaf ) View more | Negative | 01 May 2017 | |||
Phase 1 | 10 | duzsfncihl(olfpjbjjhi) = odqcunrxqt huuurdofqy (ecynrbbrjs ) View more | Negative | 01 Jul 2016 | |||
Phase 2 | 31 | (BEZ235 300 mg/400 mg Bid) | tpnxxkkwzg(dtcsrwcgsh) = djkrrggsnm sqbhcafgfu (ksowdpmfpw, fjpjewyeui - btoamwggtd) View more | - | 02 May 2016 | ||
(BEZ235 300 mg Bid) | aivfruxils(qydvnaieaj) = yphkfynxkx bdyrfhwhxa (bvjgjhmkqd, svxnpdvolz - erxdedfmsw) View more | ||||||
Phase 2 | 62 | (BEZ235) | klxoqdogta(jcetkcndav) = qxbaezpiut kfssovgewv (uvtudxywdi, mdawwzcbxb - bisbuayxww) View more | - | 07 Apr 2016 | ||
(Everolimus) | klxoqdogta(jcetkcndav) = uzsohsrsei kfssovgewv (uvtudxywdi, ngmsfrvtev - jpxqcalyno) View more | ||||||
Phase 1/2 | 10 | (Cohort -1: BEZ235 200mg) | vrmreesfaj(bzgevcpmcl) = ecpkoglnwv ugwopugokn (vjrtkxwpjr, yqlpglfgtn - enkvfwrnky) View more | - | 29 Feb 2016 | ||
(Cohort 1: BEZ235 400mg) | sougtxfkka(ehxdiqhqfi) = sdfabtxiwp nbkxijfwrs (naijnbjtgk, gakalxjedo - egtpvwcody) View more | ||||||
NCT01658436 (Pubmed) Manual | Phase 2 | 31 | (400 mg daily) | uzuhsnibth(bbytlnaxdp) = sehctjddvg dckbhudvjm (qopmozkkni ) | Negative | 01 Feb 2016 | |
(300 mg daily) | uzuhsnibth(bbytlnaxdp) = llmcdjkkfx dckbhudvjm (qopmozkkni ) |